Pfizer asks FDA to OK Covid-19 booster shots for all adults
Skip to main content
  • Home
  • Economy
    • Aviation
    • Bazaar
    • Budget
    • Industry
    • NBR
    • RMG
    • Corporates
  • Stocks
  • Analysis
  • World+Biz
  • Sports
  • Features
    • Book Review
    • Brands
    • Earth
    • Explorer
    • Fact Check
    • Family
    • Food
    • Game Reviews
    • Good Practices
    • Habitat
    • Humour
    • In Focus
    • Luxury
    • Mode
    • Panorama
    • Pursuit
    • Wealth
    • Wellbeing
    • Wheels
  • Epaper
  • More
    • Subscribe
    • Videos
    • Thoughts
    • Splash
    • Bangladesh
    • Supplement
    • Infograph
    • Archive
    • COVID-19
    • Games
    • Long Read
    • Interviews
    • Offbeat
    • Podcast
    • Quiz
    • Tech
    • Trial By Trivia
    • Magazine
  • বাংলা
The Business Standard

Sunday
January 29, 2023

Sign In
Subscribe
  • Home
  • Economy
    • Aviation
    • Bazaar
    • Budget
    • Industry
    • NBR
    • RMG
    • Corporates
  • Stocks
  • Analysis
  • World+Biz
  • Sports
  • Features
    • Book Review
    • Brands
    • Earth
    • Explorer
    • Fact Check
    • Family
    • Food
    • Game Reviews
    • Good Practices
    • Habitat
    • Humour
    • In Focus
    • Luxury
    • Mode
    • Panorama
    • Pursuit
    • Wealth
    • Wellbeing
    • Wheels
  • Epaper
  • More
    • Subscribe
    • Videos
    • Thoughts
    • Splash
    • Bangladesh
    • Supplement
    • Infograph
    • Archive
    • COVID-19
    • Games
    • Long Read
    • Interviews
    • Offbeat
    • Podcast
    • Quiz
    • Tech
    • Trial By Trivia
    • Magazine
  • বাংলা
SUNDAY, JANUARY 29, 2023
Pfizer asks FDA to OK Covid-19 booster shots for all adults

Coronavirus chronicle

UNB/AP
10 November, 2021, 09:05 am
Last modified: 10 November, 2021, 09:15 am

Related News

  • Twin shocks call for stronger domestic policy response
  • US CDC still looking at potential stroke risk from Pfizer bivalent Covid shot
  • China rings in Lunar New Year with most Covid rules lifted
  • WHO recommends that China monitor excess Covid-19 mortality
  • China retaliates against S.Korea, Japan over Covid curbs

Pfizer asks FDA to OK Covid-19 booster shots for all adults

Pfizer is submitting early results of a booster study in 10,000 people to make its case that it’s time to further expand the booster campaign

UNB/AP
10 November, 2021, 09:05 am
Last modified: 10 November, 2021, 09:15 am
Vials of the Pfizer-BioNTech Covid-19 vaccine sit in a cooler before being thawed at a pop-up Covid-19 vaccination site in the Bronx borough of New York on Tuesday, Jan. 26, 2021. On Tuesday, Nov. 9, 2021, Pfizer asked US regulators to allow boosters of its Covid-19 vaccine for anyone 18 or older, a step that comes amid concern about increased spread of the coronavirus with holiday travel and gatherings. Photo: UNB/AP
Vials of the Pfizer-BioNTech Covid-19 vaccine sit in a cooler before being thawed at a pop-up Covid-19 vaccination site in the Bronx borough of New York on Tuesday, Jan. 26, 2021. On Tuesday, Nov. 9, 2021, Pfizer asked US regulators to allow boosters of its Covid-19 vaccine for anyone 18 or older, a step that comes amid concern about increased spread of the coronavirus with holiday travel and gatherings. Photo: UNB/AP

Pfizer asked US regulators Tuesday to allow boosters of its Covid-19 vaccine for anyone 18 or older, a step that comes amid concern about increased spread of the coronavirus with holiday travel and gatherings.

Older Americans and other groups particularly vulnerable to the virus have had access to a third dose of the Pfizer and BioNTech vaccine since September. But the Food and Drug Administration has said it would move quickly to expand boosters to younger ages if warranted.

Pfizer is submitting early results of a booster study in 10,000 people to make its case that it's time to further expand the booster campaign.

While all three vaccines used in the US continue to offer strong protection against severe Covid-19 illness and death, the shots' effectiveness against milder infection can wane over time.

Pfizer's new study concluded a booster could restore protection against symptomatic infection to about 95%, even as the extra-contagious delta variant was surging. Side effects were similar to those seen with the company's first two shots.

A median of 11 months after their last Pfizer vaccination, trial participants were given either a third dose or a dummy shot. Researchers tracked any infections that occurred at least a week later, and so far have counted five cases of symptomatic Covid-19 among booster recipients compared to 109 cases among people who got dummy shots.

The Biden administration had originally envisioned boosters for all adults, but faced a stinging setback in September when the FDA's scientific advisers rejected extra Pfizer doses for everyone. The panel wasn't convinced that young healthy people needed another dose, particularly when most of the world's population remains unvaccinated, and instead recommended boosters just for certain groups — one of a series of decisions about extra doses for all of the three vaccines used in the US

The current rules: People who initially received Pfizer or Moderna vaccinations are eligible for a booster six months later if they're 65 or older, or are at high risk of Covid-19 because of health problems or their job or living conditions. Because the single-dose Johnson & Johnson vaccine hasn't proven as effective as its two-dose competitors, any J&J recipient can get a booster at least two months later.

Also, anyone eligible for a booster doesn't have to stick with their initial vaccination type and can get a different company's vaccine, what's called mixing and matching.

About 194 million Americans are fully vaccinated. Under today's policies, authorities already estimated about 2 of every 3 vaccinated adults could qualify for a booster within the next few months. Many who don't meet the criteria often score an extra shot because many vaccine providers don't check qualifications.

FDA spokeswoman Alison Hunt said the agency would review Pfizer's application "as expeditiously as possible," but would not set a timeline for a decision. She also said the FDA hasn't yet decided whether to convene its panel of outside experts to vet the data.

If the FDA authorizes Pfizer's request for expanded boosters, the Centers for Disease Control and Prevention then will make recommendations for how to use them.

Globally, boosters also are a hodge-podge. Some countries restrict them to older or medically fragile people while others have few restrictions. Israel, for example, has allowed Pfizer boosters for anyone 12 and older. Canada's health regulator on Tuesday authorized Pfizer boosters for people 18 and older.

Top News / World+Biz

Pfizer / FDA / Covid -19 / booster

Comments

While most comments will be posted if they are on-topic and not abusive, moderation decisions are subjective. Published comments are readers’ own views and The Business Standard does not endorse any of the readers’ comments.

Top Stories

  • Import slowdown to affect economic growth: ADB country head
    Import slowdown to affect economic growth: ADB country head
  • Photo: Collected
    Foreign loan pledges fall 60% in H1  
  • Debapriya Bhattacharya. Illustration: TBS
    Business leaders' role in corruption is also questionable: Debapriya

MOST VIEWED

  • FIKE PHOTO: Medical staff moves a patient into a fever clinic at a hospital, as coronavirus disease (COVID-19) outbreaks continue in Shanghai, China, December 19, 2022. REUTERS/Aly Song
    China approves two domestically developed Covid drugs
  • People walk with their luggage at a railway station during the annual Spring Festival travel rush ahead of the Chinese Lunar New Year, as the coronavirus disease (COVID-19) outbreak continues, in Shanghai, China January 16, 2023. REUTERS/Aly Song
    Holiday trips within China surge after lifting of Covid curbs
  • Photo: Collected
    India launches world’s 1st intranasal Covid vaccine
  • A vial of the Pfizer-BioNTech coronavirus disease (COVID-19) booster vaccine targeting BA.4 and BA.5 Omicron sub variants is pictured at Skippack Pharmacy in Schwenksville, Pennsylvania, U.S., September 8, 2022. REUTERS/Hannah Beier
    US CDC still looking at potential stroke risk from Pfizer bivalent Covid shot
  •  A medical worker checks the IV drip treatment of a patient lying on a bed in the emergency department of a hospital, amid the coronavirus disease (COVID-19) outbreak in Shanghai, China, January 5, 2023. REUTERS/Staff
    China says Covid deaths down by nearly 80 percent
  • Sean Bagley, 14, receives the Pfizer-BioNTech coronavirus disease (COVID-19) booster vaccine targeting BA.4 and BA.5 Omicron sub variants at Skippack Pharmacy in Schwenksville, Pennsylvania, U.S., September 8, 2022. REUTERS/Hannah Beier
    Updated Covid vaccines prevented illness from latest variants -CDC

Related News

  • Twin shocks call for stronger domestic policy response
  • US CDC still looking at potential stroke risk from Pfizer bivalent Covid shot
  • China rings in Lunar New Year with most Covid rules lifted
  • WHO recommends that China monitor excess Covid-19 mortality
  • China retaliates against S.Korea, Japan over Covid curbs

Features

Nandita Sharmin's journey to give organic skincare a new identity

Nandita Sharmin's journey to give organic skincare a new identity

9h | Mode
Illustration: TBS

'The silver lining is that the worst is sort of behind us': Hamid Rashid, UN economist

13h | Panorama
Photo: Bloomberg

BuzzFeed and AI are a match made in fad city

11h | Panorama
Snipe in flight. Photo: Enam Ul Haque

Baikka Beel: 'A world where snipe work late'

1d | Panorama

More Videos from TBS

Sarika Sabrin is waiting for a good film

Sarika Sabrin is waiting for a good film

3h | TBS Entertainment
Take your football game to the next level at Next Level academy

Take your football game to the next level at Next Level academy

4h | TBS SPORTS
“Investments risky without consistent policy, reliable data”- SK Bashir Uddin

“Investments risky without consistent policy, reliable data”- SK Bashir Uddin

5h | TBS Round Table
What does Shahrukh has in his 770 million dollar property?

What does Shahrukh has in his 770 million dollar property?

1d | TBS Entertainment

Most Read

1
Picture: Collected
Bangladesh

US Embassy condemns recent incidents of visa fraud

2
Illustration: TBS
Banking

16 banks at risk of capital shortfall if top 3 borrowers default

3
Photo: Collected
Splash

Hansal Mehta responds as Twitter user calls him 'shameless' for making Faraaz

4
A frozen Beyond Burger plant-based patty. Photographer: AKIRA for Bloomberg Businessweek
Bloomberg Special

Fake meat was supposed to save the world. It became just another fad

5
Bapex calls candidates for job test 9 years after advert!
Bangladesh

Bapex calls candidates for job test 9 years after advert!

6
Representational Image
Banking

Cash-strapped Islami, Al-Arafah and National turn to Sonali Bank for costly fund

EMAIL US
[email protected]
FOLLOW US
WHATSAPP
+880 1847416158
The Business Standard
  • About Us
  • Contact us
  • Sitemap
  • Privacy Policy
  • Comment Policy
Copyright © 2023
The Business Standard All rights reserved
Technical Partner: RSI Lab

Contact Us

The Business Standard

Main Office -4/A, Eskaton Garden, Dhaka- 1000

Phone: +8801847 416158 - 59

Send Opinion articles to - [email protected]

For advertisement- [email protected]